Regulatory

CLINUVEL
Posted by CLINUVEL
August 29, 2023

Appendix 4G and Corporate Governance Statement

Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 29, 2023

Dividend/Distribution – CUV

Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 29, 2023

Appendix 4E & Annual Report

Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
June 30, 2023

Notification regarding unquoted securities

CLINUVEL today released a notification regarding unquoted securities.

Read More
CLINUVEL
Posted by CLINUVEL
June 30, 2023

Two grounds of Appeal upheld by NICE Panel

In an announcement released today, CLINUVEL provided an updated on the outcome...

Read More
CLINUVEL
Posted by CLINUVEL
June 29, 2023

Notification of cessation of securities

CLINUVEL today released a notification regarding cessation of securities.

Read More
CLINUVEL
Posted by CLINUVEL
June 28, 2023

Change of Director’s Interest Notice

CLINUVEL today released a notification regarding a change of Director’s interest.

Read More
CLINUVEL
Posted by CLINUVEL
May 9, 2023

CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients

CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...

Read More
CLINUVEL
Posted by CLINUVEL
May 1, 2023

Expansion of CLINUVEL’s global porphyria programs

CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...

Read More
CLINUVEL
Posted by CLINUVEL
March 30, 2023

Investor Presentation - NYC Nasdaq Event

CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...

Read More
CLINUVEL
Posted by CLINUVEL
March 20, 2023

First stroke patient treated with PRÉNUMBRA® Instant

CLINUVEL has started its second stroke trial (CUV803) with the first patient...

Read More
CLINUVEL
Posted by CLINUVEL
March 13, 2023

Statement on Silicon Valley Bank (SVB)

Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
Lachlan Hay
Posted by Lachlan Hay
March 10, 2023
Lachlan Hay
Posted by Lachlan Hay
March 9, 2023

Commercial Update SCENESSE®

CLINUVEL today published its 2022 status report on the commercial distribution of...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2023

Relief from Quarterly Reporting

Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More